Wyeth Wins Round One Of 5,000 In Hormone Therapy Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
Research findings about breast cancer risk from Premarin are mixed, Wyeth maintains.
You may also be interested in...
Wyeth Modifies Premarin Warnings Slightly
Data from estrogen-alone and estrogen-plus-progestin substudies of the Women’s Health Initiative now included in black box for Premarin products.
Wyeth To Make Decision On Redux Settlement Amendment Next Week
Wyeth will decide the week of Jan. 10 whether to accept an amendment to the Redux class action settlement that covers claimants with less serious medical conditions, CEO Robert Essner said
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.